3 Shocking Facts You Didn’t Know About Emcure’s IPO Boom!
Emcure Pharmaceuticals, a global pharma company, had a strong IPO debut on July 10th. The offering attracted high investor interest, with shares listing at a 31.5% premium. The company manufactures a wide range of drugs and operates across 70 countries.
CONTENTS: 3 Shocking Facts You Didn’t Know About Emcure’s IPO Boom!
Strong investor demand for Emcure IPO
3 Shocking Facts You Didn’t Know About Emcure’s IPO Boom!
Emcure Pharmaceuticals made an impressive market debut on July 10, listing at Rs 1,325.05, which is a 31.5 percent premium over the issue price of Rs 1,008. The IPO, conducted from July 3 to July 5, was a book-built issue worth Rs 1,952.03 crores and attracted substantial investor interest. Qualified Institutional Buyers (QIBs) led the demand, subscribing 92.94 times their allotted shares.
Non-institutional investors followed, purchasing 42.57 times their quota. Emcure’s employees also showed considerable interest, bidding 7.9 times their allotted portion, while retail investors subscribed 6.33 times their reserved shares.
Emcure IPO details provided
The IPO includes a fresh issue of 0.79 crore shares, amounting to Rs 800 crores, and an offer for sale of 1.14 crore shares, totaling Rs 1,152.03 crores. The price band for the IPO was set between Rs 960 and Rs 1,008 per share. The allotment of shares was finalized on July 8, and Emcure Pharmaceuticals shares were listed on the BSE and NSE on July 10.
The IPO was managed by Kotak Mahindra Capital Company Limited, Axis Capital Limited, J.P. Morgan India Private Limited, and Jefferies India Private Limited, with Link Intime India Private Ltd serving as the registrar.
Emcure: Global Pharma Manufacturer
Emcure Pharmaceuticals, an Indian-based company, specializes in developing, manufacturing, and globally marketing pharmaceutical products across various therapeutic areas. Their product portfolio includes orals, injectables, and biotherapeutics, reaching over 70 countries worldwide.
The company operates 13 manufacturing facilities in India, producing a variety of dosage forms including oral solids, oral liquids, and injectables, both liposomal and lyophilized. These facilities are also equipped to manufacture biotherapeutics and complex active pharmaceutical ingredients (APIs), such as chiral molecules, iron molecules, and cytotoxic products.
Check out TimesWordle.com for all the latest news
You must be logged in to post a comment.